Escitalopram

Generic Name
Escitalopram
Brand Names
Cipralex, Lexapro
Drug Type
Small Molecule
Chemical Formula
C20H21FN2O
CAS Number
128196-01-0
Unique Ingredient Identifier
4O4S742ANY
Background

Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic citalopram. It is used to restore serotonergic function in the treatment of depression and anxiety. Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible for the vast majority of citalopram’s clinical activity, with some evidence suggesting that the R-enantiomer of racemic citalopram actively dampens the activity of escitalopram rather than existing simply as an inactive enantiomer. Amongst SSRIs, escitalopram exerts the highest degree of selectivity for the serotonin transporter (SERT) relative to other off-targets which may explain its lower rates of adverse effects as compared to other agents in this class. Escitalopram also differentiates itself from other SSRIs via allosteric action on its target - this may be the mechanism responsible for its observed superior efficacy and faster onset compared to other SSRIs.

Indication

Escitalopram is indicated for the acute and maintenance treatment of major depressive disorder (MDD) in adults and pediatric patients 12 years old and older and for the acute treatment of generalized anxiety disorder (GAD) in adults and pediatric patients 7 years old and older. It is additionally indicated for symptomatic relief of obsessive-compulsive disorder (OCD) in Canada.

Associated Conditions
Anxiety, Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD)
Associated Therapies
-

Exploring Biomarkers for Depression

First Posted Date
2011-08-26
Last Posted Date
2018-05-01
Lead Sponsor
Wyss Institute at Harvard University
Target Recruit Count
51
Registration Number
NCT01424111
Locations
🇺🇸

Depression Clinical and Research Program, MGH, Boston, Massachusetts, United States

A Study to Evaluate the Effect of Danoprevir/Ritonavir on the Pharmacokinetics of Escitalopram and S-Demethylcitalopram in Healthy Volunteers

First Posted Date
2011-08-17
Last Posted Date
2016-11-02
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
20
Registration Number
NCT01418274

Predicting Medication Response in Obsessive Compulsive Disorder

First Posted Date
2011-07-28
Last Posted Date
2013-01-31
Lead Sponsor
Sunnybrook Health Sciences Centre
Target Recruit Count
26
Registration Number
NCT01404871
Locations
🇨🇦

Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada

🇨🇦

The Centre for Addiction and Mental Health, Toronto, Ontario, Canada

Influence of Escitalopram on Fear Conditioning

Phase 4
Completed
Conditions
Interventions
First Posted Date
2011-07-20
Last Posted Date
2014-06-11
Lead Sponsor
Massachusetts General Hospital
Target Recruit Count
65
Registration Number
NCT01398514

Bioequivalence Study Comparing Two Formulations of Escitalopram

Phase 1
Completed
Conditions
Interventions
First Posted Date
2011-07-15
Last Posted Date
2012-12-10
Lead Sponsor
H. Lundbeck A/S
Target Recruit Count
32
Registration Number
NCT01395433
Locations
🇳🇱

NL001, Leiden, Netherlands

Lexapro for the Treatment of Traumatic Brain Injury (TBI) Depression & Other Psychiatric Conditions

First Posted Date
2011-06-08
Last Posted Date
2016-10-24
Lead Sponsor
Johns Hopkins University
Target Recruit Count
16
Registration Number
NCT01368432
Locations
🇺🇸

Johns Hopkins University, Baltimore, Maryland, United States

Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression

First Posted Date
2011-06-08
Last Posted Date
2015-10-12
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
976
Registration Number
NCT01369095
Locations
🇺🇸

Mclean Hospital, Belmont, Massachusetts, United States

🇺🇸

Virginia Commonwealth University, Richmond, Virginia, United States

🇺🇸

Pacific Clinical Research Medical Group, Orange, California, United States

and more 45 locations

Electroencephalography (EEG) Signal Processing

First Posted Date
2011-06-08
Last Posted Date
2011-11-30
Lead Sponsor
St. Joseph's Healthcare Hamilton
Target Recruit Count
150
Registration Number
NCT01369290
Locations
🇨🇦

St. Joseph's Healthcare, Centre for Mountain Health Services, Hamilton, Ontario, Canada

Investigation of Tibolone and Escitalopram in Perimenopausal Depression

First Posted Date
2011-06-07
Last Posted Date
2015-03-31
Lead Sponsor
The Alfred
Target Recruit Count
2
Registration Number
NCT01368068
Locations
🇦🇺

The Alfred Hospital, Melbourne, Victoria, Australia

Vortioxetine (Lu AA21004) 10 and 20 mg for Treatment of Major Depressive Disorder With Sexual Dysfunction

First Posted Date
2011-06-02
Last Posted Date
2014-10-09
Lead Sponsor
Takeda
Target Recruit Count
447
Registration Number
NCT01364649
© Copyright 2024. All Rights Reserved by MedPath